

TABLE OF CONTENTS

December 25, 2006

No. 2022

BUSINESS

- 1 Pfizer to Continue Launching Series of New Drugs: President Iwasaki
 - New Marketing Structure Introduced in December
 - Trials of Torcetrapib Terminated
- 2 Chugai to Copromote Otsuka's Antiplatelet Agent Pletaal
- 3 Pazufloxacin Can Now Be Used as 1st-Choice Drug: Toyama, MPC
- 3 SMO Group Holds CRC Training Seminar
- 4 **BUSINESSNEWSINBRIEF**
 - LTT Bio-Pharma Ties Up with Cipla for Nano Steroids
 - Fuji Biomedix to Acquire Stake in Biototech of South Korea
 - Nippon Shinyaku Terminates Licensing Agreement with Roche
 - Arimidex Overtakes Tamoxifen in Early Breast Cancer Therapy: AstraZenca
 - Yamato Logistics Aims to Expand Distribution Business in Medical Field
- 5 **NEWPRODUCTS**
 - Nippon Organon: Marvelon 28 Low-dose Oral Contraceptive
 - Banyu: Antihypertensive Combination PREMINENT
 - Otsuka: Injectable Abilify in the US
- 6 Biopharmaceuticals Expected to Show Strongest Growth in Future: JHSF Survey
- 6 **Seminar**
 - DTC Ads Should Be Acceptable to Doctors: EBMs Seminar
 - Control over Drug Production Strengthened in China Following Accidents

GENERIC

- 8 JGPMA Proposes "Drug Benefit Standard Price System"
- 8 *Koroshō* Exchanges Opinions with NPhA on Generics, Distribution
- 9 Tie-ups of *Hansha* Spreading to Kanto, Shikoku: Mr Eguchi

REGULATORY

- 10 Transfer Price Taxation System to Be Revised in FY2007
- 10 System That Fairly Awards Innovation Needed: WG for New Industry Vision
- 11 *Koroshō* Hears from 5 Parties to Promptly Bring New Drugs to Patients
- 11 Nippon Keidanren Leaders Exchange Opinions with *Koroshō* Leaders
- 12 PMDA to Increase Transparency on Posting of Ex-Employees of Companies
 - 156 Applications Reviewed in 1st Half of FY2006
- 12 **REGULATORYNEWSINBRIEF**
 - 425 ADR Cases Judged Eligible for Relief in 1st Half: PMDA
- 13 **Commentary**
 - Mr Abe Issues Japanese Version of Blair Declaration

R&D

- 14 Wyeth, Kyushu Univ. Moving Forward with Their R&D Alliance

- Global Research Partners Quadruple in 3 Years: Mr Andersen
 - Building Strong Neuroscience Pipeline via Partnership: Dr Pangalos
 - Kyushu Univ. Needs to Partner with More Global Companies: Mr Takata
- 15 Sanofi-aventis to Start Large Epidemiological Study in Cerebral Infarction Patients
 - Many People Are Unaware of Risk of Recurrence
 - Clopidogrel as Effective as Ticlopidine, and Safer: Prof. Suzuki
 - 16 AstraZeneca to Simultaneously Start All PI Trials Worldwide
 - 16 Novartis Highlights Strong R&D Pipeline
 - 17 **R&DNEWSINBRIEF**
 - Meiji Seika to Codevelop Antibody Drugs with Symphogen
 - TS-1 Reduces Risk of Death after Gastric Cancer Surgery: Taiho
 - Algorithm Developed to Predict Effects of Hepatitis C Treatment
 - Nexavar Fail to Meet Primary Endpoint in PIII Trial: Bayer, Onyx
 - DSP to Take Back Overseas Development Rights to Lurasidone
 - PharmaDesign Receives Top Prizes in CASP Contest in the US

SELF-MEDICATION

- 18 Risk Classification for OTC Drugs Nearly Complete: PFSB

MEDICAL DEVICES

- 19 Asahi Kasei Medical, Kuraray Medical to Integrate Businesses
 - New Company to Do 50% of Business Overseas
- 18 **MEDICALDEVICENEWSINBRIEF**
 - Olympus to Market VisEn Medical's Molecular Imaging Systems in Asia
 - Olympus, Terumo Creates Joint Venture for Biomaterials Business

MEDICAL FACILITIES & NURSING CARE

- 20 Financial Support to Be Provided to Fewer Patients with Ulcerative Colitis, Parkinson's Disease
- 20 Reducing Number of "Cancer Refugees" Would Save ¥522.7 Billion
- 21 No Increase in Resistance to Tamiflu Observed: Roche
- 21 Allergic Rhinitis Affects QOL, Reduces Productivity: Prof. Okamoto
- 22 Influenza Preventive Effects of Catechin Gargle Reported
- 23 **Survey**
 - Cost of Informed Consent Rose ¥60 Mil. Per Hospital in 7 Years
 - Nat'l Univ. Hospitals Moving Aggressively to Hire More Nurses
 - Hospital Income Down About 2% Due to Medical Fee Revision: *Nichiyokyo*
 - Survey Shows Tough Working Conditions for Young Doctors